Cerus Corporation (NASDAQ:CERS) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
|
Submission of Matters to a Vote of Security Holders |
On June7, 2017, Cerus Corporation (the Company) held its 2017
Annual Meeting of Stockholders (the Annual Meeting). The
following is a brief description of each matter voted upon at the
Annual Meeting, as well as the number of votes cast for or
against each matter and the number of abstentions and broker
non-votes with respect to each matter. A more complete
description of each matter is set forth in the Companys
definitive proxy statement filed with the Securities and Exchange
Commission on April28, 2017 (the Proxy Statement).
Proposal 1
The Companys stockholders elected each of the three nominees
named below to the Board of Directors, to serve until the 2020
Annual Meeting of Stockholders or until his respective successor
has been duly elected and qualified.
| Nominee | For | Withheld | BrokerNon-Votes | |||
| TimothyB.Anderson | 39,931,743 | 18,360,428 | 32,618,382 | |||
| Bruce C. Cozadd | 32,898,548 | 25,393,623 | 32,618,382 | |||
| WilliamM.Greenman | 40,991,188 | 17,300,983 | 32,618,382 |
Proposal 2
The Companys stockholders approved an amendment and restatement
of the Companys 2008 Equity Incentive Plan, as amended, to
increase the aggregate number of shares of common stock
authorized for issuance thereunder by 6,000,000 shares and to
make certain other changes thereto as described in the Proxy
Statement.
| For | Against | Abstain | BrokerNon-Votes | |||
| 35,408,204 | 22,487,456 | 396,511 | 32,618,382 |
Proposal 3
The Companys stockholders approved, on an advisory basis, the
compensation of the Companys named executive officers as
disclosed in the Proxy Statement.
| For | Against | Abstain | BrokerNon-Votes | |||
| 40,020,880 | 4,530,518 | 13,740,773 | 32,618,382 |
Proposal 4
The Companys stockholders ratified the selection of Ernst Young
LLP as the independent registered public accounting firm for the
Company for its fiscal year ending December31, 2017.
| For | Against | Abstain | ||
| 73,048,560 | 3,971,283 | 13,890,710 |
No other matters were submitted for stockholder action at the
Annual Meeting.
About Cerus Corporation (NASDAQ:CERS)
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company’s INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.
